Heat shock protein 70, erythropoietin, and cancer.
Sizer
Kurt C
KC
D002277:Carcinoma / Q000188:drug therapy / Q000378:metabolism*; D018450:Disease Progression; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D018840:HSP70 Heat-Shock Proteins / Q000096:biosynthesis* / Q000502:physiology*; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D017467:Receptors, Erythropoietin / Q000378:metabolism*; D011994:Recombinant Proteins; D016896:Treatment Outcome
D018840:HSP70 Heat-Shock Proteins; D017467:Receptors, Erythropoietin; D011994:Recombinant Proteins; D004921:Erythropoietin